zPREDICTA
zPREDICTA, based in San Jose, CA, specializes in developing advanced 3D cell culture models that closely mimic human tissues for drug efficacy screening and other pharmaceutical applications.
Company Overview
zPREDICTA, formerly known as Ixchel Scientific, is a healthcare company based in San Jose, CA, USA. The company operates within the drug discovery and delivery sub-industry, focusing on developing organ-specific, physiologically-relevant 3D cell culture models. zPREDICTA's platform provides a 1-to-1 reconstruction of human tissues and accurately predicts clinical outcomes. The company was part of the S15 batch of Y Combinator and has since been acquired.
Healthcare Solutions and Services
zPREDICTA specializes in creating 3D cell culture models that reconstruct human tissues with high fidelity. The platform accounts for major components of both cellular and extracellular environments. Customers use these models to screen the efficacy of anticancer compounds, including immuno-oncology agents, assess mechanisms of drug resistance, and evaluate off-target toxicity. The platform's compatibility spans any drug class, multiple tissue and cell types, and various readouts, making it a versatile tool in drug discovery and development.
High Correlation with Clinical Outcomes
Clinical study data demonstrates a high correlation between drug efficacy measured on zPREDICTA's platform and actual clinical response. This capability supports the platform's use in reliably predicting clinical outcomes. The accurate modeling of human tissues ensures that clients can trust the results for guiding their drug development processes, including rescuing failed drug candidates.
Strategic Location and Market Presence
With its headquarters in San Jose, CA, USA, zPREDICTA operates primarily within the United States and America/Canada regions. The company's strategic location in a technological hub aids in collaborations and access to cutting-edge innovations in healthcare. Being part of Y Combinator's S15 batch has further enhanced its visibility and reach within the industry.